Relenopride

Drug Profile

Relenopride

Alternative Names: SKL-IBS; YKP-10811; YKP-GI

Latest Information Update: 17 Jul 2015

Price : $50

At a glance

  • Originator SK biopharmaceuticals
  • Developer SK biopharmaceuticals; SK Chemicals
  • Class Benzamides; Carbamates; Fluorobenzenes; Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation; Irritable bowel syndrome

Most Recent Events

  • 26 Jun 2015 Relenopride is still in phase-II development for Constipation in USA and South Korea
  • 01 Dec 2014 SK Chemicals completes a phase II trial in Irritable bowel syndrome and Constipation in South Korea (NCT02082457)
  • 01 Dec 2014 SK Life Science completes a phase II trial in Constipation in USA (NCT01989234)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top